Cargando…

Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India

BACKGROUND: Dolutegravir (DTG) is widely used for the management of naïve and treatment-experienced HIV-infected patients. Low-level viremia (LLV) is common in patients receiving nonnucleoside reverse transcriptase inhibitor- and protease inhibitor-containing regimens. However, the incidence of LLV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Atul K., Patel, Ketan K., Pujari, Sanjay, Patel, Jagdish K., Kumar, Ambuj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579596/ https://www.ncbi.nlm.nih.gov/pubmed/34765935 http://dx.doi.org/10.4103/ijstd.IJSTD_34_20

Ejemplares similares

P437 Diagnostic utility of serum beta D glucan test to prescribe antifungal treatment and its effect on patient's outcome: a study from a tertiary care center in Western India
por: Patel, Kamlesh, et al.
Publicado: (2022)

Management of cryptococcal meningitis in HIV-infected patients: Experience from western India
por: Patel, Atul K., et al.
Publicado: (2010)

Assessment of self-reported adherence to ART and patient's virological/CD4 response in a tertiary care clinic and government free ART clinic
por: Patel, Rushin, et al.
Publicado: (2021)

Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India
por: Patel, Ketan K., et al.
Publicado: (2010)

Living Related Donor Renal Transplant in Human Immunodeficiency Virus Infected Patient: Case Reports from Tertiary Care Hospital in Western India
por: Dalal, Sonal, et al.
Publicado: (2014)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Clinical Outcome of Novel H1N1 (Swine Flu)-Infected Patients During 2009 Pandemic at Tertiary Referral Hospital in Western India
por: Patel, Ketan K., et al.
Publicado: (2013)

Response to the comments received on a case report SARS-CoV-2 viral sepsis with meningoencephalitis
por: Dharsandiya, Mitkumar, et al.
Publicado: (2021)

Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy
por: Gaifer, Zied, et al.
Publicado: (2020)

Low-level residual viremia and risk of virological failure
por: Cologni, G, et al.
Publicado: (2010)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial
por: Li, Jonathan Z, et al.
Publicado: (2019)

Virological Suppression and Its Associated Factors of Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective Study in Ethiopia
por: Mehari, Eden Abetu, et al.
Publicado: (2021)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study
por: Patel, Atul, et al.
Publicado: (2020)

Psychiatric Symptoms in Patients Receiving Dolutegravir
por: Fettiplace, Anna, et al.
Publicado: (2017)

Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India
por: Pujari, Sanjay, et al.
Publicado: (2008)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
por: Kumarasamy, N., et al.
Publicado: (2011)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

Nonsuppressible viremia during HIV-1 therapy meets molecular virology
por: Emery, Ann, et al.
Publicado: (2023)

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
por: Wang, Ruolan, et al.
Publicado: (2023)

Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Medisetty, Mahender Kumar, et al.
Publicado: (2021)

Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil
por: Gomes, Samara Tatielle M., et al.
Publicado: (2017)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Elderly Diabetic Patient with Surgical Site Mucormycosis Extending to Bowel
por: Patel, Atul K, et al.
Publicado: (2010)

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
por: Pena, M J, et al.
Publicado: (2018)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland
por: Waqas, Sarmad, et al.
Publicado: (2016)

Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence
por: Punekar, Y S, et al.
Publicado: (2021)

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
por: Rhee, Soo-Yon, et al.
Publicado: (2017)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
por: Rodrigues, Janine, et al.
Publicado: (2023)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3b6g0oiosmpis0bqaknf4eovbo